Molecular biological design of novel antineoplastic therapies

Abstract

Novel therapies represent a new strategy for the development of anticancer agents. New targets derived from the knowledge of the molecular structure and genetic defects has been useful in developing anticancer drugs that prolong or stabilise the progression of tumours with minimal systemic toxicities. In this review, the mechanism of action and the most significant trials regarding monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis and cyclooxygenase inhibitor-based therapies, farnesyl transferase inhibitors and proteasome inhibitors are discussed. The potential biological end points and toxicities are also described. In conclusion, novel therapies present a promising class of anticancer agents, acting through different mechanisms and offering a new perspective in the treatment of cancer.

• angiogenesis
• cancer
• cyclooxygenase inhibitors
• farnesyl transferase inhibitors
• monoclonal antibodies
• novel therapies
• proteosome inhibitors
• Ras
• tyrosine kinase inhibitors